Related Experiment Video
Updated: Dec 28, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus
S Vázquez Estévez1, U Anido2, M Lázaro3
1Medical Oncology Department, Hospital Universitario Lucus Augusti (Lugo), Dr. Ulises Romero, s/n, 27003, Lugo, Spain. Sergio.Vazquez.Estevez@sergas.es.
Background:
This article describes and compares approved targeted therapies and the newer immunotherapy agents.
Materials And Methods:
This article especially performs an in-depth review of currently available data for tivozanib, explaining its mechanism of action, its safety profile and its role as an efficacy drug in the management of renal cancer.
Results:
Despite the fact that the treatment of advanced RCC has been dramatically modified in recent years, durable remissions are scarce and it remains a lethal disease. For first- and second-line therapy, there is now growing evidence to guide the selection of the appropriate treatment.
Conclusions:
Several TKIs are standard of care at different settings. Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.
